(Q37810104)

23 August 2017

title

Lestaurtinib: a multi-targeted FLT3 inhibitor (English)

1 reference

23 August 2017

Amir T Fathi

1

1 reference

23 August 2017

Mark Levis

series ordinal

2

1 reference

23 August 2017

publication date

1 February 2009

1 reference

Expert Review of Hematology

23 August 2017

published in

1 reference

23 August 2017

volume

2

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

17-26

1 reference

23 August 2017

cites work

Acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Cytogenetics in acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Acute myeloid leukemia: epidemiology and etiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Acute myeloid leukemia and myelodysplastic syndromes in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

21 January 2018

Acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Targeting FLT3 for the treatment of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

FLT3 inhibition in acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Expression of a distinctive BCR-ABL oncogene in Ph1-positive acute lymphocytic leukemia (ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

FLT3: ITDoes matter in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Pediatric AML primary samples with FLT3/ITD mutations are preferentially killed by FLT3 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

21 January 2018

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

The novel Trk receptor tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits antitumor efficacy against human pancreatic carcinoma (Panc1) xenograft growth and in vivo invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Combinations of the FLT3 inhibitor CEP-701 and chemotherapy synergistically kill infant and childhood MLL-rearranged ALL cells in a sequence-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Review of UCN-01 development: a lesson in the importance of clinical pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17474086.2.1.17

21 January 2018

Identifiers

DOI

10.1586/17474086.2.1.17

1 reference

23 August 2017

1 reference